Strategies and challenges for the next generation of therapeutic antibodies (Q34111699)

31 July 2017

1 reference

title

Strategies and challenges for the next generation of therapeutic antibodies (English)

1 reference

31 July 2017

1 reference

Alain Beck

1 reference

31 July 2017

Thierry Wurch

series ordinal

1 reference

31 July 2017

Christian Bailly

series ordinal

1 reference

31 July 2017

Nathalie Corvaia

series ordinal

1 reference

31 July 2017

publication date

1 May 2010

1 reference

Nature Reviews Immunology

31 July 2017

published in

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

345-352

1 reference

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

31 July 2017

cites work

1 reference

What's fueling the biotech engine--2008

21 January 2018

1 reference

5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland

31 March 2020

1 reference

Therapeutic antibodies and derivatives: from the bench to the clinic

31 March 2020

1 reference

mAb therapeutic products and risk management

31 March 2020

1 reference

Fully human antibodies from transgenic mouse and phage display platforms

31 March 2020

1 reference

Development trends for therapeutic antibody fragments

31 March 2020

1 reference

Respiratory syncytial virus market

31 March 2020

1 reference

Optimization of Fc-mediated effector functions of monoclonal antibodies

31 March 2020

1 reference

Evolution of anti-CD20 monoclonal antibody therapeutics in oncology

31 March 2020

1 reference

Discovery and development of biopharmaceuticals: current issues

31 March 2020

1 reference

FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

31 March 2020

1 reference

Therapeutic antibodies for autoimmunity and inflammation

31 March 2020

1 reference

Monoclonal antibodies: versatile platforms for cancer immunotherapy

31 March 2020

1 reference

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

31 March 2020

1 reference

More is less -- combining targeted therapies in metastatic colorectal cancer

31 March 2020

1 reference

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

31 March 2020

1 reference

Integrins in cancer: biological implications and therapeutic opportunities

31 March 2020

1 reference

Insulin-like growth factor receptor type I as a target for cancer therapy

31 March 2020

1 reference

Drug development of MET inhibitors: targeting oncogene addiction and expedience

31 March 2020

1 reference

Antibody-based identification of cell surface antigens: targets for cancer therapy

31 March 2020

1 reference

Extending mass spectrometry contribution to therapeutic monoclonal antibody lead optimization: characterization of immune complexes using noncovalent ESI-MS.

31 March 2020

1 reference

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

31 March 2020

1 reference

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

31 March 2020

1 reference

The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies

31 March 2020

1 reference

Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody.

31 March 2020

1 reference

Determination of Fab-hinge disulfide connectivity in structural isoforms of a recombinant human immunoglobulin G2 antibody

31 March 2020

1 reference

The effect of Fc glycan forms on human IgG2 antibody clearance in humans

31 March 2020

1 reference

Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins

31 March 2020

1 reference

Structural and functional characterization of disulfide isoforms of the human IgG2 subclass

31 March 2020

1 reference

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

31 March 2020

1 reference

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses

31 March 2020

1 reference

Glycosylation as a strategy to improve antibody-based therapeutics

31 March 2020

1 reference

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

31 March 2020

1 reference

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection

31 March 2020

1 reference

Toward an effective targeted chemotherapy for multiple myeloma

31 March 2020

1 reference

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

31 March 2020

1 reference

Antibody-drug conjugates ace the tolerability test

31 March 2020

1 reference

Catumaxomab: clinical development and future directions

31 March 2020

1 reference

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

31 March 2020

1 reference

Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules

31 March 2020

1 reference

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

31 March 2020

1 reference

Considerations for the development of therapeutic monoclonal antibodies

31 March 2020

1 reference

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

31 March 2020

1 reference

Manufacture of recombinant polyclonal antibodies

31 March 2020

1 reference

Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation.

31 March 2020

1 reference

Engineered protein scaffolds as next-generation antibody therapeutics.

31 March 2020

1 reference

31 March 2020

2009 FDA drug approvals

1 reference

31 March 2020

1 reference

A European perspective on immunogenicity evaluation

31 March 2020

1 reference

How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations

31 March 2020

1 reference

When binding is enough: nonactivating antibody formats.

31 March 2020

1 reference

New challenges to medicare beneficiary access to mAbs

31 March 2020

1 reference

Industrialization of mAb production technology: the bioprocessing industry at a crossroads

31 March 2020

1 reference

Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies

31 March 2020

1 reference

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins

31 March 2020

1 reference

Economic issues with follow-on protein products

31 March 2020

1 reference

Toward biosimilar monoclonal antibodies

31 March 2020

1 reference

4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland

31 March 2020

1 reference

Structural characterization of a human Fc fragment engineered for extended serum half-life

31 March 2020

1 reference

Gearing up for follow-on biologics

31 March 2020

1 reference

Genetic prognostic and predictive markers in colorectal cancer

31 March 2020

1 reference

Biomarkers of response and resistance to antiangiogenic therapy

31 March 2020

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

31 March 2020

1 reference

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

31 March 2020

1 reference

Replacing the complementarity-determining regions in a human antibody with those from a mouse

31 March 2020

1 reference

Phage antibodies: filamentous phage displaying antibody variable domains

31 March 2020

1 reference

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

31 March 2020

1 reference

Antigen-specific human antibodies from mice comprising four distinct genetic modifications

31 March 2020

1 reference

The IGF-I receptor in cell growth, transformation and apoptosis

31 March 2020

1 reference

12 December 2020

European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK

1 reference

12 December 2020

The RAV12 monoclonal antibody recognizes the N-linked glycotope RAAG12: expression in human normal and tumor tissues

1 reference

12 December 2020

Antibodies to watch in 2010

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI2747

1 reference

Dimensions Publication ID

31 July 2017

1012486795

0 references

1 reference